A Phase I Randomized, Double-Blind, Placebo-Controlled Study Investigating the Safety, Tolerability, and Pharmacokinetics of Single Dose Intravenously Administered HFB30132A, a Monoclonal Antibody Against SARS-CoV-2, in Chinese Healthy Adult Subjects
Latest Information Update: 15 Mar 2022
At a glance
- Drugs Enuzovimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors HiFiBiO
Most Recent Events
- 15 Mar 2022 New trial record